An analysis of 35 clinical studies shows that off-label use of Novo Nordisk's recombinant activated factor VII, an FDA-approved treatment for hemophilia, significantly increases the risk of arterial clots and related complications. Data show that about 5.5% of patients who took the anti-clotting drug developed arterial thrombosis, compared with 3.2% of those given placebo.

Related Summaries